June 26, 2024 07:09 AM EDT

Lyell reports patient death, early responses in solid tumor CAR-T trial

Lei Lei Wu

News Reporter

In an early-stage clinical trial with a handful of patients, Lyell Immunopharma’s experimental CAR-T therapy for solid tumor cancers showed hints of efficacy but also …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Lyell reports patient death, early responses in solid tumor CAR-T trial

Lei Lei Wu

News Reporter

Sign up to read this article for free.

Why the Supreme Court's overrule of Chevron has major implications for the FDA

J&J details Phase 3 success of autoimmune disease drug, touting broader range than argenx’s Vyvgart

FDA rejects Rocket Pharma’s ultra-rare immune disease gene therapy over manufacturing

Inside BARDA's multibillion-dollar effort to fund long-shot biotechs for Covid

Scientists unveil new way to make large changes to genes, and no CRISPR is required

Merck calls ACIP's pneumococcal recommendation a 'missed opportunity,' advocates for expanding age group

Lyell re­ports pa­tient death, ear­ly re­spons­es in sol­id tu­mor CAR-T tri­al

Lei Lei Wu

News Reporter

Sign up to read this article for free.

more like this

Why the Supreme Court's over­rule of Chevron has ma­jor im­pli­ca­tions for the FDA

J&J de­tails Phase 3 suc­cess of au­toim­mune dis­ease drug, tout­ing broad­er range than ar­genx’s Vyv­gart

FDA re­jects Rock­et Phar­ma’s ul­tra-rare im­mune dis­ease gene ther­a­py over man­u­fac­tur­ing

In­side BAR­DA's multi­bil­lion-dol­lar ef­fort to fund long-shot biotechs for Covid

Sci­en­tists un­veil new way to make large changes to genes, and no CRISPR is re­quired

Mer­ck calls ACIP's pneu­mo­coc­cal rec­om­men­da­tion a 'missed op­por­tu­ni­ty,' ad­vo­cates for ex­pand­ing age group

Lyell reports patient death, early responses in solid tumor CAR-T trial

Why the Supreme Court's overrule of Chevron has major implications for the FDA

J&J details Phase 3 success of autoimmune disease drug, touting broader range than argenx’s Vyvgart

FDA rejects Rocket Pharma’s ultra-rare immune disease gene therapy over manufacturing

Inside BARDA's multibillion-dollar effort to fund long-shot biotechs for Covid

Scientists unveil new way to make large changes to genes, and no CRISPR is required

Merck calls ACIP's pneumococcal recommendation a 'missed opportunity,' advocates for expanding age group